Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Circumventing resistance to kinase-inhibitor therapy.

× No keyword cloud information.

45 in total

1. A positive role for c-Abl in Atm and Atr activation in DNA damage response.

Authors: X Wang; L Zeng; J Wang; J F L Chau; K P Lai; D Jia; A Poonepalli; M P Hande; H Liu; G He; L He; B Li
Journal: Cell Death Differ Date: 2010-08-27 Impact factor: 15.828

2. Imatinib spells BAD news for Bcr/abl-positive leukemias.

Authors: Scott H Kaufmann
Journal: Proc Natl Acad Sci U S A Date: 2006-09-26 Impact factor: 11.205

3. Drug discovery in jeopardy.

Authors: Pedro Cuatrecasas
Journal: J Clin Invest Date: 2006-11 Impact factor: 14.808

Review 4. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors: Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal: Transl Lung Cancer Res Date: 2016-12

Review 5. Kinase packing defects as drug targets.

Authors: Alejandro Crespo; Ariel Fernández
Journal: Drug Discov Today Date: 2007-10-30 Impact factor: 7.851

6. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.

Authors: Ariel Fernández; Angela Sanguino; Zhenghong Peng; Alejandro Crespo; Eylem Ozturk; Xi Zhang; Shimei Wang; William Bornmann; Gabriel Lopez-Berestein
Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701

7. Ligand binding and protein dynamics in lactate dehydrogenase.

Authors: J R Exequiel T Pineda; Robert Callender; Steven D Schwartz
Journal: Biophys J Date: 2007-05-04 Impact factor: 4.033

Review 8. BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Authors: Wanlong Ma; Hagop Kantarjian; Chen-Hsiung Yeh; Zhong J Zhang; Jorge Cortes; Maher Albitar
Journal: Acta Haematol Date: 2009-03-31 Impact factor: 2.195

9. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.

Authors: H Zhang; D Trachootham; W Lu; J Carew; F J Giles; M J Keating; R B Arlinghaus; P Huang
Journal: Leukemia Date: 2008-04-03 Impact factor: 11.528

10. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture.

Authors: Jelena Klawitter; Yan Ling Zhang; Jost Klawitter; Nora Anderson; Natalie J Serkova; Uwe Christians
Journal: Biomed Chromatogr Date: 2009-12 Impact factor: 1.902